MASSACHUSETTS GENERAL HOSPITAL

Alzamend Neuro completed a $5 million private placement months ahead of schedule to fund five Phase II clinical trials of AL001 "Lithium in Brain" studies at Massachusetts General Hospital.

Penumbra has completed enrollment of 100 patients in the pivotal STORM-PE randomized controlled trial, comparing computer assisted vacuum thrombectomy plus anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism.

Multiple studies presented at MAD-ID 2025 demonstrate fidaxomicin's superior efficacy over vancomycin in preventing C. difficile infection recurrence among high-risk patient populations.

Dr. Erin E. Mauney at Massachusetts General Hospital is conducting the first clinical trial examining psilocybin's effects on treatment-resistant irritable bowel syndrome (IBS).

TPN-101, a first-in-class LINE-1 reverse transcriptase inhibitor, has been selected for inclusion in the Phase 2/3 HEALEY ALS Platform Trial based on promising Phase 2 data.

PSMA PET imaging has revolutionized prostate cancer detection and management, particularly in biochemical recurrence settings, with multiple FDA-approved agents now available including gallium-68 PSMA-11, piflufolastat F 18, and flotufolastat F 18.

Mythic Therapeutics will present updated dose escalation data from its Phase 1 KisMET-01 study of MYTX-011, a cMET-targeting antibody-drug conjugate, at the 2025 ASCO Annual Meeting.

The FDA has granted Breakthrough Device Designation to Prevencio's HART CADhs test, an AI-based multi-protein blood test for detecting obstructive coronary artery disease.

Hillhurst Biopharmaceuticals has received $6.3 million in grants, including $2 million from The Michael J. Fox Foundation and $4.3 million from the Farmer Family Foundation in collaboration with Massachusetts General Hospital.

Massachusetts General Hospital has enrolled the first patient in a trial evaluating RELiZORB's efficacy in managing exocrine pancreatic insufficiency in tube-fed pancreatitis patients.